Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVNNASDAQ:MLYSNASDAQ:MNPRNASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$18.28-7.1%$19.11$13.30▼$30.03$897.07M1.07259,638 shs254,358 shsMLYSMineralys Therapeutics$14.70+1.6%$13.75$8.24▼$18.38$953.35M-0.3442,701 shs530,043 shsMNPRMonopar Therapeutics$38.40-1.0%$36.41$1.72▼$54.30$234.79M1.11359,079 shs12,120 shsPHVSPharvaris$17.10+1.6%$15.21$11.51▼$25.50$894.16M-2.8573,871 shs84,111 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-3.43%+5.58%+5.35%-13.45%-14.09%MLYSMineralys Therapeutics-7.49%+3.73%+16.61%+40.94%+5.16%MNPRMonopar Therapeutics-9.72%-6.70%+30.49%-19.73%+888.56%PHVSPharvaris-9.81%-2.55%+17.86%-3.99%-25.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.1771 of 5 stars3.60.00.00.02.74.20.0MLYSMineralys Therapeutics2.3184 of 5 stars3.51.00.00.01.85.00.0MNPRMonopar Therapeutics2.7445 of 5 stars3.45.00.00.02.12.50.0PHVSPharvaris1.9792 of 5 stars3.53.00.00.02.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.25Buy$40.33120.61% UpsideMLYSMineralys Therapeutics 3.00Buy$33.00124.57% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3344.11% UpsidePHVSPharvaris 3.00Buy$39.00128.07% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, MLYS, ELVN, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.003/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.002/24/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/13/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $24.002/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/APHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.64N/AN/AN/AN/A-67.97%-62.40%5/12/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.60N/AN/AN/AN/A-107.21%-87.57%5/8/2025 (Estimated)PHVSPharvaris-$109.18M-$2.68N/AN/AN/AN/A-38.52%-36.69%5/14/2025 (Estimated)Latest MNPR, MLYS, ELVN, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PHVSPharvaris-$0.80N/AN/AN/AN/AN/A5/13/2025Q1 2025ELVNEnliven Therapeutics-$0.51N/AN/AN/AN/AN/A5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02N/AN/AN/AN/AN/A5/8/2025N/AMNPRMonopar Therapeutics-$0.65N/AN/AN/AN/AN/A4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/12/2025Q4 2024MLYSMineralys Therapeutics-$1.00-$0.98+$0.02-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A17.4417.44MLYSMineralys TherapeuticsN/A14.0214.02MNPRMonopar TherapeuticsN/A5.415.41PHVSPharvarisN/A19.0819.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%MLYSMineralys Therapeutics84.46%MNPRMonopar Therapeutics1.83%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics29.20%MLYSMineralys Therapeutics33.24%MNPRMonopar Therapeutics34.90%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableMLYSMineralys Therapeutics2864.88 million33.27 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableMNPR, MLYS, ELVN, and PHVS HeadlinesRecent News About These CompaniesPrice T Rowe Associates Inc. MD Increases Stock Holdings in Pharvaris (NASDAQ:PHVS)May 6 at 4:04 AM | marketbeat.comCantor Fitzgerald Forecasts Pharvaris FY2025 EarningsMay 3, 2025 | marketbeat.comPharvaris (PHVS) Shares Cross Above 200 DMAMay 2, 2025 | nasdaq.comPharvaris (NASDAQ:PHVS) Coverage Initiated at Cantor FitzgeraldMay 2, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on Pharvaris FY2025 EarningsMay 2, 2025 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Here's WhyMay 1, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Coverage Initiated by Analysts at Cantor FitzgeraldMay 1, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Pharvaris N.V. (PHVS) with Overweight RecommendationApril 30, 2025 | msn.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's WhyApril 27, 2025 | marketbeat.comRock Springs Capital Management LP Purchases 18,200 Shares of Pharvaris (NASDAQ:PHVS)April 23, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Up 7.8% - Still a Buy?April 17, 2025 | marketbeat.comFmr LLC Has $103.43 Million Holdings in Pharvaris (NASDAQ:PHVS)April 16, 2025 | marketbeat.comPharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial PositionApril 14, 2025 | tipranks.comQ1 Earnings Estimate for Pharvaris Issued By Leerink PartnrsApril 12, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q1 Earnings (NASDAQ:PHVS)April 12, 2025 | marketbeat.comWhat is Wedbush's Estimate for Pharvaris FY2029 Earnings?April 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Hits New 12-Month Low - Here's What HappenedApril 11, 2025 | marketbeat.comPharvaris’s Strategic Advancements and Strong Financial Position Drive Buy RatingApril 10, 2025 | tipranks.comPharvaris (NASDAQ:PHVS) Stock Price Down 8.4% - Here's What HappenedApril 9, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSApril 9, 2025 | marketbeat.comPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last yearApril 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR, MLYS, ELVN, and PHVS Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$18.28 -1.41 (-7.15%) Closing price 03:59 PM EasternExtended Trading$18.30 +0.01 (+0.07%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Mineralys Therapeutics NASDAQ:MLYS$14.70 +0.24 (+1.63%) Closing price 03:59 PM EasternExtended Trading$14.68 -0.02 (-0.10%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Monopar Therapeutics NASDAQ:MNPR$38.40 -0.38 (-0.99%) Closing price 03:59 PM EasternExtended Trading$38.98 +0.58 (+1.51%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Pharvaris NASDAQ:PHVS$17.10 +0.27 (+1.60%) Closing price 04:00 PM EasternExtended Trading$17.10 0.00 (0.00%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
